Table 1.

Hematological parameters that demonstrated significant difference based on the age and sex of TB patients before initiation of anti-TB drugs compared with after completion of the intensive phase of treatment

			Before treatment	After treatment	P-value
RBC × 106/ μl	Sex	Male	4.27 ± 0.92	4.43 ± 0.92	0.235
		Female	4.24 ± 0.72	4.42 ± 0.68	0.143
	Age	5 – 25	4.26 ± 0.77	4.42 ± 0.89	0.320
		26 – 44	4.37 ± 0.75	4.33 ± 0.68	0.747
		45 – 65	4.09 ± 1.01	4.58 ± 0.92	0.030*
Hgb (g/dl)	Sex	Male	12.7 ± 2.1	11.8 ± 1.5	0.000*
		Female	12.8 ± 2.1	11.8 ± 1.9	0.000*
	Age	5 – 25	12.9 ± 2	11.8 ± 1.8	0.000*
		26 – 44	12.9 ± 1.8	12 ± 1.4	0.001*
		45 – 65	12.4 ± 2.5	11.5 ± 1.8	0.000*
HCT (%)	Sex	Male	38.6 ± 6	35.8 ± 4.4	0.000*
		Female	38.9 ± 5.5	35.7 ± 5.4	0.000*
	Age	5 – 25	39.1 ± 5.7	35.7 ± 5.5	0.000*
		26 – 44	38.9 ± 4.9	36.6 ± 4	0.001*
		45 – 65	37.9 ± 6.8	34.7 ± 5	0.000*
MCV (fl)	Sex	Male	88.4 ± 6.9	89.4 ± 9.1	0.036*
		Female	89.4 ± 6.7	90.9 ± 5.1	0.143
	Age	5 – 25	89.4 ± 7.3	90.2 ± 5.1	0.486
		26 – 44	88.3 ± 5.8	91.2 ± 5.8	0.013*
		45 – 65	88.7 ± 7.6	90.4 ± 5.2	0.241
MCH (pg)	Sex	Male	28.9 ± 3.3	29.6 ± 2.3	0.143
		Female	29.2 ± 2.6	30.1 ± 2	0.040*
	Age	5 – 25	29.3 ± 3	29.7 ± 2.1	0.427
		26 – 44	29.1 ± 3.1	29.7 ± 2.5	0.253
		45 – 65	28.5 ± 3	30 ± 2	0.012*
MCHC (%)	Sex	Male	32.7 ± 2	32.7 ± 1.3	0.878
		Female	32.6 ± 1.4	33.1 ± 1.1	0.049*
	Age	5 – 25	32.6 ± 1.6	32.9 ± 1.3	0.357
		26 – 44	33 ± 1.9	32.7 ± 1.3	0.390
		45 – 65	32.2 ± 1.6	33.1 ± 1	0.003*
RDW CV (%)	Sex	Male	14.4 ± 1.4	14.2 ± 1.2	0.311
		Female	14.5 ± 1.7	13.9 ± 1.2	0.02*
	Age	5 – 25	14.4 ± 1.4	14.1 ± 1.3	0.143
		26 – 44	14.3 ± 1.4	14.1 ± 1.2	0.477
		45 – 65	14.6 ± 1.8	14 ± 1.1	0.059
PLT × 103/μl	Sex	Male	267 ± 106	232 ± 109	0.031*
		Female	270 ± 101	250 ± 86	0.169
	Age	5 – 25	258 ± 105	250 ± 116	0.697
		26 – 44	274 ± 101	246 ± 72	0.085
		45 – 65	275 ± 105	216 ± 108	0.006*

* = significant association